Shinpoong Pharmaceutical Applies for Phase 3 Clinical Trial Plan of COVID-19 Treatment Piramax in the UK

[Asia Economy Reporter Minji Lee] Shinpoong Pharmaceutical announced on the 18th that it has applied to the UK Medicines and Healthcare products Regulatory Agency for a Phase 2 and 3 clinical trial to comparatively evaluate the efficacy and safety of Piramex tablets in COVID-19 patients.

The company plans to additionally apply for clinical trial plans in Poland and Russia on the 25th, Argentina on the 28th, and Chile on the 10th of next month, besides the UK.

Shinpoong Pharmaceutical stated, “The existing domestic Phase 3 clinical trial is part of a multinational clinical trial, and clinical trials will be conducted in a total of six countries including Korea to obtain approval.”